0001493152-22-035770.txt : 20221216 0001493152-22-035770.hdr.sgml : 20221216 20221216165150 ACCESSION NUMBER: 0001493152-22-035770 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221216 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221216 DATE AS OF CHANGE: 20221216 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PALISADE BIO, INC. CENTRAL INDEX KEY: 0001357459 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 522007292 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33672 FILM NUMBER: 221468579 BUSINESS ADDRESS: STREET 1: 7750 EL CAMINO REAL, SUITE 5200 CITY: CARLSBAD STATE: CA ZIP: 92009 BUSINESS PHONE: (858) 704-4900 MAIL ADDRESS: STREET 1: 7750 EL CAMINO REAL, SUITE 5200 CITY: CARLSBAD STATE: CA ZIP: 92009 FORMER COMPANY: FORMER CONFORMED NAME: Seneca Biopharma, Inc. DATE OF NAME CHANGE: 20200127 FORMER COMPANY: FORMER CONFORMED NAME: Neuralstem, Inc. DATE OF NAME CHANGE: 20060324 8-K 1 form8-k.htm
0001357459 false 0001357459 2022-12-16 2022-12-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 16, 2022

 

PALISADE BIO, INC.

(Exact name of Registrant as Specified in Its Charter)

 

Delaware   001-33672   52-2007292

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

7750 El Camino Real

Suite 5200

   
Carlsbad, California   92009
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (858) 704-4900

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.01 per share   PALI   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01Other Events.

 

On December 16, 2022, Palisade Bio, Inc. provided an update on its U.S. Phase 2 Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions. A copy of the press release is attached to this report as Exhibit 99.01.

 

Item 9.01 Financial Statement and Exhibits.

 

Exhibit

No.

  Description
99.01   Press Release dated December 16, 2022
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: December 16, 2022 Palisade Bio, Inc.
       
      /s/ J.D. Finley
    By: J.D. Finley
      Interim Chief Executive Officer

 

 

EX-99.01 2 ex99-01.htm

 

Exhibit 99.01

 

 

Palisade Bio Provides Update on U.S. Phase 2 Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions

 

Topline data readout from study expected in first half of 2023

 

Carlsbad, CA – December 16, 2022Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is providing an update on its U.S. Phase 2 study evaluating LB1148 for reduction in intra-abdominal adhesions in subjects following elective bowel resection (PROFILE).

 

The Company enrolled a total of 35 of the planned 70 patients in its Phase 2 study. Of the patients enrolled, 31 have completed their first surgery, and nine have completed a second surgery, which is an inflection point for data under the current study protocol. Palisade believes that the data collected to date is sufficient for its evaluation purposes, including an evaluation of its risk profile, and for such reason, the Company is voluntarily ceasing enrollment in the trial. Palisade expects to report topline data from the 35 patients in the first half of 2023.

 

Herbert B. Slade, MD, FAAAAI, Chief Medical Officer of Palisade Bio stated, “We are optimistic about the topline data expected in the first half of 2023 related to the achievement of the primary endpoint of the Phase 2 adhesions study. We remain encouraged by the data demonstrated by LB1148 and are committed to driving its development in a manner that we believe best positions us to provide patient benefit, and ultimately approval.”

 

The Company is currently designing a dose optimization study for all indications to determine if a different dosing protocol would enhance the risk profile while simultaneously providing efficacy. It is anticipated that this study will generate pharmacokinetic and pharmacodynamic data across multiple doses in patients, with enrollment expected to commence in the first half of 2023.

 

“Since joining the Company as CMO last month, I have had the opportunity to review the LB1148 data generated to-date and the current clinical development plan. I believe there is a lot of potential for LB1148 to fundamentally transform the way physicians mitigate the risks of acute and chronic GI complications from surgery. I also believe it is critical for us to put our best foot forward in advancing this important program and see a unique opportunity to fine tune the dose and dosing regimen of LB1148. All of this considered, we have decided to move forward with a planned dose optimization study which will guide our future development,” added Dr. Slade.

 

The Company’s U.S. Phase 2 clinical trial of LB1148 is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study in patients undergoing elective bowel resection surgery. This trial is designed to evaluate whether patients treated with LB1148 experience reduction in formation of post-surgical intra-abdominal adhesions and accelerate the return of GI function in subjects undergoing elective bowel resection with planned stoma take-down.

 

“As a company, we are committed to taking a fundamental, strategic approach to drug development. We believe the decision to stop enrollment and analyze the data from the current enrolled subjects will provide valuable insight as we work to further advance our lead program, LB1148,” concluded JD Finley, interim Chief Executive Officer of Palisade Bio.

 

 

 

 

About Palisade Bio

 

Palisade Bio is a biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The Company utilizes over three decades of research and established science that links the role of intestinal barrier biology and human disease to develop novel therapeutics that target and improve the integrity of the intestinal barrier.

 

The Company’s lead program, LB1148, is a broad-spectrum serine protease inhibitor that acts to neutralize digestive enzymes, potentially reducing intestinal damage. In clinical studies, LB1148 has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially accelerating the time to return of postoperative bowel function. LB1148 is currently being evaluated in a Phase 2 study to evaluate reduction in intra-abdominal adhesions, return of gastrointestinal function, and prevention of post-operative ileus in subjects undergoing elective bowel resection (PROFILE).

 

The Company believes that addressing the disruption of the intestinal barrier can fundamentally change the way diseases are treated and establish new standards of patient care. For more information, please go to www.palisadebio.com.

 

Forward Looking Statements

 

This communication contains “forward-looking” statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: progress of studies, including opening additional clinical trial sites, timing of results or data, progress and completion of patient enrollment, including timing thereof and the Company’s co-development partner’s expectation to complete enrollment; regulatory progress and strategy, including potential registration and commercialization of LB1148; the extent of the cash runway; the closing of the underwritten public offering; and expected proceeds from financings. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon the Company’s current expectations. Forward-looking statements involve risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the Company’s ability to advance its clinical programs, the uncertain and time-consuming regulatory approval process; the Company’s ability to achieve additional financing to fund future operations and the Company’s ability to comply with the continued listing requirements for Nasdaq. Additional risks and uncertainties can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission (“SEC”) on March 17, 2022, Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed with the SEC on November 14, 2022, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

 

Investor Relations Contact

 

JTC Team, LLC

Jenene Thomas

833-475-8247

PALI@jtcir.com

 

Source: Palisade Bio

 

 

GRAPHIC 3 ex99-01_001.jpg begin 644 ex99-01_001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*# +8# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#U'Q5KGB+3 M+M(M+L=-^S,F3=W]XL:ANXVY!XXKDI/%WB4OME\8>$+9NZ!BV/;/>MKQMX5. MI^)+#51IAU14@:%K:1@L0.6$;5TOPA:+U*.%8C]:?M(1T:_ MJ&#K5O>4DEYO]$FQEMXM\5,P\CQ#X0U C@QBXL[DV\@AE\Q&( .0?3FN-N-#\R)Y+CP_P"%[Y$4EOL[*C #GL177^ ;'3K7 MP]Y^FZ=V"@?4FJ\&K:;:N#S^[7_ -#% M>3:E9^#K3P)8WVF7BQ^)0D3%8)B7\SC=D=L<_C5QA=')4JN#L?04T\5O"TL\ MJ11*,L[L% ^I-);W,%W$);::.:,\!XW# _B*\Q\?W]]>^%_#OAZ0'^TM7:$3 MKWP,9R/]XC\C4WPQ=]#UC7?"%PQ+6!ZD=:=<74%I"9KF:.&(<%Y'"J/Q->V]RJ_>,,@;'UQ7F7C^QO[KP1X:DAMY[G3H%B>]A M@SN*[%P>.W7Z9H\&6W@B[\46]_X=O[K3[I(RKZ:[%?-..^[.1[ ^]/DTN3[5 M\_+8]3N+F"TB,MS/'#&#@O(X4?F:6&>*XA6:"1)8F&5=&# _0BO-OB<\FNZU MH7A"W<@WH7M;F& M=%."T3A@#Z<5X9XE;PW'\4]:;Q-!<2VA1/+%N#NW[5ZX(XQFO2OAVOATZ#/- MX9AN(K-[A@XGSN+@#/4GC!%$H65QPJN4FCI9-4T^*1HY;ZV1U."K3*"/J,U8 M66-XQ(CJT9&0P.01ZYKB[.]T.VO]734;99)S?R$,;0R\8&.0I]^*M^&WAEL- M:DLU,=@TK^1">"GR_-\O\()YQ7.IW9Z=3#F.V64=4#$Y(]\ M UT%OX=TBWM?LZZ? ZXPS2(&9O?.HVR32SGYSZ@9XKU6LS6]'CUJP-K) M//!\P8/"^"#[^H]JB=-2UZG7A<9*DO9OX6[]=/N:N>>Z+:Z/XAU-K$^''MF7 M/FS6]PV(\>H/OQ7I]K;16=K%;0+LBB4(B^@%5]*TFST>S6ULX@B#ECU9SZD] MS5ZBG#E6NY.,Q/MY^[?E6R;;^>IS?CZQNM2\$:G:64#SW$B*$C3JWS U1\)> M"='L=&TNZN=$MX]42!#*\B9=9,%O'6DZM:W%YK463*-\F% QGTZY YKFH=.\0>+?&VD:G<>&1H<5C()9YVX:7!S MCMGIC\3S7KV**%.W0)4KO5GDQ\':YXI\Q"\^]>IT4<[V%["-[]=SR&( M>*O#?CGQ#J-AX:FOX;Z;Y&)VC:#D$5KZ)H/B+Q%XMM_$OBBWCLH[)2+.R1LD M$]S_ #_*O1Z,4.8U12ZZ'DFI6OB+2?B3J^L6/AE]4M[B-8T+@;>B\C\L5W'A M'4=5U"SN&U30AI#)(!'$.CC'+?TKHZ,4G*ZV'&GRNZ9RUG>7FE7>IQMH]_.L MMX\J21("I4@8ZGVJ;3;:[FNM6U&6T:U%W&J1P,1O.U2-S8X!.]E9OU\O\CF+31;BY\%Z?9.3;7UNJ21EA_JY%.1GV_QJ=->OHH_+N]!O M_M2\$6ZAXV/J&SP/K6_BC%'+;83K8VCV-V;ZYU;456.ZG41I K9 5$,8Y )[DGDT5M8HII6,YS EX-101.SCH 4 pali-20221216.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 pali-20221216_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 pali-20221216_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Dec. 16, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 16, 2022
Entity File Number 001-33672
Entity Registrant Name PALISADE BIO, INC.
Entity Central Index Key 0001357459
Entity Tax Identification Number 52-2007292
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 7750 El Camino Real
Entity Address, Address Line Two Suite 5200
Entity Address, City or Town Carlsbad
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92009
City Area Code (858)
Local Phone Number 704-4900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol PALI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001357459 2022-12-16 2022-12-16 iso4217:USD shares iso4217:USD shares 0001357459 false 8-K 2022-12-16 PALISADE BIO, INC. DE 001-33672 52-2007292 7750 El Camino Real Suite 5200 Carlsbad CA 92009 (858) 704-4900 false false false false Common Stock, par value $0.01 per share PALI NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://palisadebio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-01.htm pali-20221216.xsd pali-20221216_lab.xml pali-20221216_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "pali-20221216_lab.xml" ] }, "presentationLink": { "local": [ "pali-20221216_pre.xml" ] }, "schema": { "local": [ "pali-20221216.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "PALI", "nsuri": "http://palisadebio.com/20221216", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-12-16to2022-12-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://palisadebio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-12-16to2022-12-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001493152-22-035770-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-035770-xbrl.zip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end